Cystic fibrosis: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CFTR 29
• GLP-1 2
• G6PD 0
• IL-13 0
• MUC1 0
• NF1 1
• PDE4 0
• STAT3 0
• CTNNB1 0
• DMD 1
• EGFR 0
• ERK 0
• HDAC 0
• HMGB1 0
• HTT 1
• IL-1 0
• IL-17 0
• IL-4 0
• IL-6 0
• mTOR 0
• NLRP3 0
• NRF2 0
• PKD1 0
• PPAR 0
• SGLT2 0
• SMN1 1
• TLR4 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 71+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Validation of Therapeutic Efficacy Targeting the Splicing Variants in Cystic Fibrosis and CFTR Pathologies

  NCT05100823· University Hospital, Montpellier· Updated 18 Sept 2025

  “Enrolment period completed and sufficient number of enrolments to achieve study objectives”Registry text, quoted unchanged. Source

• Terminated

  Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)

  NCT05392855· University of Missouri-Columbia· Updated 20 Sept 2024

  “Low recruitment, low interest from participant population”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis

  NCT05095246· Krystal Biotech, Inc.· Updated 14 Aug 2023

  “Pandemic, logistical, and recruitment challenges”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Assessment of CFTR-Modulator Treatment in Cystic Fibrosis Lung Disease Using Novel Structural and Functional MRI

  NCT04391322· The Hospital for Sick Children· Source

• TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age

  NCT07048574· State University of New York at Buffalo· Source

• Safety of Stopping Pancreatic Enzyme Replacement Therapy in Children With Improved Pancreatic Function After Highly Effective Modulator Therapy

  NCT07632768· Indiana University· Source

• Establishment of a Primary Epididymal Cell Model From Epididymal Samples to Study CFTR Gene Regulation

  NCT06045702· University Hospital, Brest· Source

• A study to test how well BI 3720931 is tolerated and whether it improves lung function in people with cystic fibrosis (LenticlairTM 1)

  2023-503281-23-00· Boehringer Ingelheim International GmbH· Source

• Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI

  NCT02848560· Children's Hospital Medical Center, Cincinnati· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Organoids 20
• CRISPR-Cas Systems 12
• Gene Expression Profiling 13
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 16
• Exome Sequencing 5
• Proteomics 12
• Metabolomics 9
• Mass Spectrometry 4
• Flow Cytometry 2
• Immunohistochemistry 3
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 21
• Machine Learning 6
• Deep Learning 3
• Cohort Studies 36
• Genome-Wide Association Study 3

• Efficient AI-supported quantification of network structures in SEM imaged human mucus: a detailed protocol.

  Am J Physiol Lung Cell Mol Physiol, Jul 2026

• CFTR modulator therapy reshapes airway inflammation in cystic fibrosis: Insights from proteomics and machine learning.

  J Cyst Fibros, Jul 2026

• Machine learning analysis of continuous glucose monitoring identifies a novel dysglycemic phenotype found in most people with cystic fibrosis.

  J Cyst Fibros, Apr 2026

• Cross-Disease Breathomics by PTR-TOF-MS: Multiclass Machine Learning and Network Remodeling Across Asthma, COPD, Cystic Fibrosis, and Lymphangioleiomyomatosis.

  Int J Mol Sci, Apr 2026

• [Application and research progress of artificial intelligence in the diagnosis and treatment of rare lung diseases].

  Zhonghua Jie He He Hu Xi Za Zhi, Jan 2026

• Machine Learning-Augmented Graphene Transistor Biosensing: Quantitative Platform Validation and Immunotesting of Hepatitis E.

  ACS Sens, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.